CN114099555B - Lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation - Google Patents
Lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation Download PDFInfo
- Publication number
- CN114099555B CN114099555B CN202111332410.2A CN202111332410A CN114099555B CN 114099555 B CN114099555 B CN 114099555B CN 202111332410 A CN202111332410 A CN 202111332410A CN 114099555 B CN114099555 B CN 114099555B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- lipoteichoic acid
- eluent
- aggregation
- acetate buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002253 acid Substances 0.000 title claims abstract description 70
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 58
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 57
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 57
- 230000002401 inhibitory effect Effects 0.000 title abstract description 12
- 230000006933 amyloid-beta aggregation Effects 0.000 title abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 29
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 12
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 7
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 7
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 6
- 235000004279 alanine Nutrition 0.000 claims abstract description 6
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 239000003480 eluent Substances 0.000 claims description 12
- 239000007974 sodium acetate buffer Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 9
- 239000011574 phosphorus Substances 0.000 claims description 9
- 229910052698 phosphorus Inorganic materials 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000002390 rotary evaporation Methods 0.000 claims description 6
- 230000008021 deposition Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 claims description 2
- 238000005571 anion exchange chromatography Methods 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 235000015141 kefir Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- -1 injectable solution Substances 0.000 claims 1
- 238000009630 liquid culture Methods 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002776 aggregation Effects 0.000 abstract description 16
- 238000004220 aggregation Methods 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 10
- 235000013376 functional food Nutrition 0.000 abstract description 10
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 6
- 230000006934 amyloid beta 42 aggregation Effects 0.000 description 14
- 239000006041 probiotic Substances 0.000 description 11
- 235000018291 probiotics Nutrition 0.000 description 11
- 238000012512 characterization method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical group CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007131 anti Alzheimer effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 125000005313 fatty acid group Chemical group 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- GUJDQIJHJQZLAT-ZRICPNARSA-N OP(O)(O)=O.OC[C@H](O)[C@H](O)[C@H](O)CO Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H](O)[C@H](O)CO GUJDQIJHJQZLAT-ZRICPNARSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000002327 glycerophospholipids Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation. The main chain of the lipoteichoic acid of the lactobacillus plantarum contains glycerol, and the side chain contains a large number of N-acetylglucosamine and alanine modifications. The lipoteichoic acid can effectively inhibit aggregation of beta-amyloid 1-42 (Abeta 42), is an Abeta 42 potential aggregation inhibitor, and can be applied to developing medicines, health products or functional foods for preventing and/or improving Alzheimer's disease.
Description
Technical Field
The invention belongs to the technical field of medicines, health-care products or foods, and particularly relates to separation and extraction, structural identification and application of novel lactobacillus plantarum lipoteichoic acid in inhibiting amyloid aggregation, in particular to application of lactobacillus plantarum MA2 serving as a beta-amyloid 1-42 (Abeta 42) aggregation inhibitor in preparing medicines, health-care products and functional foods for preventing and/or improving Alzheimer's disease.
Background
Aggregation and misfolding of amyloid proteins in cells and tissues to form toxic intermediates and amyloid fibers can lead to various biological dysfunctions. These aggregated intermediates and fibers are presumed to be associated with some neurodegenerative diseases and other disorders, such as Alzheimer's Disease (AD), parkinson's Disease (PD), type II diabetes (diabetes type II), and the like. Numerous studies have demonstrated that the more toxic fractions are oligomers or fibril intermediates, and the development of highly potent inhibitors of amyloid aggregation or functional foods against amyloid aggregation is one of the effective means of alleviating and treating these diseases. Aggregation and deposition of beta-amyloid 1-42 (aβ42) are closely related to the development of AD, and thus inhibition of aβ42 aggregation and deaggregation of aβ42 fibers have become effective pathways for development of anti-AD drugs.
Probiotics are a large class of microorganisms beneficial to the human body, including lactic acid bacteria, bifidobacteria, etc., which exert a probiotic effect by regulating intestinal microecological balance. Several studies have shown that ingestion of probiotics increases the adhesion of the intestinal flora, effectively improves intestinal micro-ecology, activates the immune system to reduce inflammation, promotes release of neurotransmitters and other beneficial metabolites, and thus improves AD and other neurodegenerative diseases. After the AD model rats ingest mixed probiotics consisting of 4 bacteria such as lactobacillus acidophilus and bifidobacterium lactis, the spatial memory capacity and the oxidative stress of the AD model rats are obviously improved. Clinical trials also evaluated the effect of a number of probiotics consisting of lactobacillus and bifidobacteria on learning and memory capacity of AD patients, and the results indicated that the minimum mental state of the tested patients was significantly improved. Thus, it is expected that a microecological therapy for improving intestinal flora by probiotics is an effective way to prevent and improve AD. The existing known probiotics for preventing and treating AD are lack of species, the complexity of intestinal flora and metabolites thereof increases the research difficulty, and the action mechanism for improving AD by utilizing intestinal microecology is not clear, which are key scientific problems for preventing and relieving AD research by using probiotics.
In recent years, the concept of a metagen has been attracting attention, and the metagen is a generic term for a probiotic metabolite component and a bacterial cell obtained by processing a probiotic. Research proves that the immunoregulation capability of some metazoan is better than that of the original viable bacteria, and the metazoan still has high physiological activity even though being treated by high temperature, ultrasonic or gastrointestinal digestive juice. Wherein teichoic acid is a representative component of metazoan, and is a key for determining the acid, alkali and heat tolerance of metazoan. Teichoic acid is a specific component of the cell wall of gram-positive bacteria, and is divided into a main chain and a side chain, wherein the main chain is generally formed by polymerizing 16-40 phosphoric acid-glycerol or phosphoric acid-ribitol, and the side chain is generally modified by hydroxyl, N-acetylglucosamine or D-alanine and the like. Teichoic acids can be classified into lipoteichoic acid (Lipoteichoic acid, LTA) and teichoic acid (Wallteichoic acid, WTA), which are anchored to the cell membrane and peptidoglycan of the cell wall, respectively. Wherein, gram positive bacterial lipoteichoic acid plays an important role in physiological functions, and mainly comprises the following aspects: (1) determining bacterial cell colonization; (2) Maintaining the balance of anions and cations in the cell walls of the bacteria, so that the bacteria are prevented from being damaged by antibacterial peptides, antibiotics and the like; (3) Recognizes and interacts with host cell-associated receptors, specifically recognizes and activates animal pattern recognition receptors and elicits corresponding immune response.
Lactobacillus plantarum MA2 is a novel lactobacillus strain separated from the subject group, and early researches show that the strain has better acid resistance, cholate resistance and antioxidation activity and has a remarkable function of improving the cognitive dysfunction of AD mice. Meanwhile, the thallus treated by high temperature or ultrasonic has good AD improving effect, so the invention firstly separates and extracts the lactobacillus plantarum MA2 lipoteichoic acid (lpTLA), identifies the structure of the lactobacillus plantarum MA2 lipoteichoic acid (lpTLA), explores the effect of the lactobacillus plantarum MA2 lipoteichoic acid in inhibiting Abeta 42 aggregation, and has important theoretical significance and application value for researching that the lipoteichoic acid improves neurodegenerative diseases and developing and preventing and/or improving AD medicines, health care products or functional foods.
Disclosure of Invention
The invention provides separation, extraction and structural identification of novel lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation, and application thereof in preparing medicines, health-care products or functional foods for preventing and/or improving AD.
Further, the lactobacillus plantarum lipoteichoic acid is lactobacillus plantarum MA2 lipoteichoic acid.
Further, the lactobacillus plantarum MA2 lipoteichoic acid is separated, extracted and structurally identified.
Further, the use of lactobacillus plantarum MA2 lipoteichoic acid in the manufacture of a medicament, a health product or a functional food for preventing and/or ameliorating a disease characterized by the aggregate deposition of aβ42.
Further, the disease is Alzheimer's disease.
Further, the lactobacillus plantarum MA2 lipoteichoic acid is present in an aqueous dispersion.
Further, the Lactobacillus plantarum MA2 lipoteichoic acid is present in an aqueous dispersion having a concentration of 0.25,0.50,1.00,2.00 mg/mL.
The lipoteichoic acid of the lactobacillus plantarum is lipoteichoic acid which is firstly separated, purified and subjected to structural identification, and also has the following advantages in the aspect of developing an Abeta 42 aggregation inhibitor, wherein the lipoteichoic acid is the function of inhibiting Abeta 42 aggregation for the first time:
the application of the lactobacillus plantarum MA2 lipoteichoic acid in inhibiting Abeta 42 aggregation is derived from lactobacillus plantarum with a probiotic effect on human bodies, and the safety is high; the lpLTA side chain obtained by the invention has higher content of N-acetylglucosamine, alanine and fatty acid groups, has important effect on physiological functions, can effectively inhibit Abeta 42 aggregation, can be used as a potential prodrug or food functional factor, is used for developing new drugs, health care products or functional foods, and is used for preventing and/or improving diseases characterized by Abeta 42 aggregation and the abnormal conception thereof.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention. In the drawings:
FIG. 1 is an infrared spectrum of Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA) in example 2 of the present invention.
FIG. 2 is a nuclear magnetic resonance hydrogen diagram of Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA) in example 2 of the present invention
FIG. 3 is a fluorescence plot of the co-culture of Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA) and Abeta 42 at various concentrations in example 3 of the present invention.
FIG. 4 is a scanning Atomic Force Microscope (AFM) scan of Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA) and Abeta 42 co-culture according to example 4 of the present invention.
Detailed Description
It should be noted that, without conflict, the embodiments of the present invention and features of the embodiments may be combined with each other.
The embodiment of the invention provides separation and extraction of novel lactobacillus plantarum lipoteichoic acid, structural identification and application thereof in inhibiting amyloid aggregation.
In the embodiment of the invention, the lactobacillus plantarum is lactobacillus plantarum MA2 separated and screened in the laboratory, and is derived from the Kefir grains of Tibetan farmhouses, and the lactobacillus plantarum is preserved in the China general microbiological culture Collection center (CGMCC) 3005 in 2009. Amyloid is beta-amyloid 1-42 (aβ42), consisting of 42 amino acids, with a molecular weight of about 4.5kDa, comprising a highly hydrophobic domain, and aggregation and deposition of this amyloid in nerve cells is closely related to the occurrence and progression of AD. The invention provides a new thought for developing Abeta 42 aggregation inhibitor and researching probiotics and metaplasia improving AD.
The embodiment of the invention provides application of lactobacillus plantarum lipoteichoic acid serving as an Abeta 42 aggregation inhibitor in preparing medicines, health-care products or functional foods for preventing and/or improving AD. The invention fully utilizes the characteristics of lactobacillus plantarum MA2 lipoteichoic acid as a prebiotic product after probiotics, has high safety, good patient adaptability and the like, can be widely applied to the development of medicines, health care products or functional foods, and further promotes the research progress of AD
Preferably, the Lactobacillus plantarum MA2 lipoteichoic acid is present in an aqueous dispersion. In other words, lactobacillus plantarum MA2 lipoteichoic acid can be taken in the form of an aqueous dispersion system, such as injection, soft capsule, beverage, oral liquid and the like.
Preferably, the Lactobacillus plantarum MA2 lipoteichoic acid is present in an aqueous dispersion having a concentration of 0.25-2.00 mg/mL. Specific concentrations were 0.25,0.50,1.00 and 2.00mg/mL.
The isolation and extraction of novel lactobacillus plantarum lipoteichoic acid, structural identification and application thereof in inhibiting amyloid aggregation are further described below with reference to specific examples.
Example 1: isolation, extraction and purification of Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA)
(1) Inoculating lactobacillus plantarum MA2 in a biosafety cabinet, and culturing to an exponential growth phase under corresponding conditions;
(2) Taking bacterial liquid, centrifuging at 7000rpm at 4 ℃ for 20min in a centrifugal cup, collecting bacterial cells, and weighing the wet weight of the bacterial cells;
(3) Resuspending wet bacteria in 0.1M sodium citrate buffer solution with pH of 4.7 according to the ratio of 1:1 (w/v), repeatedly freezing and thawing for 3 times, crushing the bacteria by using an ultrasonic crusher, wherein the amplitude is 30%, opening for 1s, closing for 1s, and the total working time is 30min;
(4) Adding equal volume of n-butanol into the mixed bacterial suspension, fully mixing, stirring for 30min on a magnetic stirrer, centrifuging at 4 ℃ and 7000rpm for 30min, and gently collecting a lower water phase;
(5) Performing rotary evaporation and dialysis on the water phase, wherein the cut-off molecular weight of a dialysis bag is 2000Da;
(6) Preparation of a2 x 20cm octyl-Sepharose column, equilibrated with 0.1M sodium acetate buffer (pH 4.7) containing 15% n-propanol;
(7) Mixing the lipoteichoic acid crude extract obtained in the step (5) with 0.1M sodium acetate buffer (pH 4.7) in a ratio of 1:5 (v/v), diluting, and passing through a column;
(8) Washing with 0.1M sodium acetate buffer (pH 4.7) of 15% n-propanol to wash out unbound impurities;
(9) The column was eluted with a gradient of 0.1M sodium acetate buffer (pH 4.7) containing 20%, 35%, 45% n-propanol, and the eluate was collected in a 10mL centrifuge tube;
(10) Detecting inorganic phosphorus in the eluent, and collecting the eluent with higher phosphorus content for rotary evaporation and dialysis;
(11) Preparation of DEAE-FastFlow (1.5 x 10 cm) anion chromatography column secondary purification of lipoteichoic acid, equilibrated column with 0.1M sodium acetate buffer (pH 4.7) containing 30% n-propanol;
(12) Pretreating and loading the dialyzed sample in the step (10), performing gradient elution by using 0-1M sodium chloride solution (prepared by 0.1M sodium acetate buffer), and collecting eluent in a 10 mL/tube;
(13) Detecting inorganic phosphorus in the eluent collected in the step (12), and collecting the eluent with higher phosphorus content for rotary evaporation and dialysis;
(14) Freezing the dialysate obtained in the step (13) for 4 hours at the temperature of minus 80 ℃ in advance, then placing the dialysate into a freeze dryer, and obtaining lactobacillus plantarum MA2 lipoteichoic acid solid after sublimation and drying, and freezing and preserving the lactobacillus plantarum MA2 lipoteichoic acid solid.
Example 2: structural identification of Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA)
(1) Infrared spectroscopic analysis
Weighing a proper amount of lpLTA powder, grinding with potassium bromide according to a mass ratio of 1:100, tabletting the mixed powder, and analyzing the functional group of lpLTA by using an infrared spectrometer, wherein the result is shown in figure 1.
Referring to FIG. 1, band 3419.95cm -1 Characterization of the-NH group, band 2929.31cm -1 Characterization of the-CH 2 、-CH 3 Radicals, band 1651.56cm -1 Characterization of the-C=O group, band 1547.32cm -1 Characterization of the-C=H group, band 1379.09cm -1 Characterization of the-P=O group, band 1231.18cm -1 Characterization of sugar residue groups, band 1038.81cm -1 Characterization of the-C-O group. The result is basically consistent with the characteristic functional group of the general structure of lipoteichoic acid, and the infrared spectrum result shows that lpLTA contains the phosphoglyceride structure, the amide, the sugar residue and the like.
(2) Nuclear magnetic resonance analysis
An appropriate amount of lpLTA powder was weighed, fully dissolved with deuterated reagent, and the H spectrum of the sample was measured on a 400MHz nmr, and the results are shown in fig. 2.
Referring to fig. 2, lplta has distinct absorption peaks at σ= 5.096,4.182,3.807,3.511,1.983,1.762,1.177 and 0.784, and in combination with standard chemical shifts, 5.096ppm is-COO vibration, 4.182 and 3.807ppm is glycerol and glycosyl vibration, 3.511ppm is N-acetyl vibration, 1.983,1.762,1.177 and 0.784ppm is N-acetylglucosamine, alanine and fatty acid vibration. As can be seen, the lpLTA backbone contains glycerol and the side chains contain N-acetylglucosamine, alanine and fatty acid modifications. Meanwhile, compared with the reported nuclear magnetic resonance result of teichoic acid (Wu et al, 2021,Journal ofBiological Chemistry,296:100384; patent application CN 104161776A-lipoteichoic acid from clostridium butyricum and the application thereof in regulating the immune response of livestock and poultry), the nuclear magnetic resonance result in FIG. 2 shows that the characteristic peak of the group with chemical shift between 0.5 and 2.0ppm is rich, and the vibration signal is strong, which indicates that the contents of N-acetylglucosamine, alanine and fatty acid groups on the lpLTA side chain are high, and the nuclear magnetic resonance result plays an important role in physiological functions.
Example 3: detection of aggregation inhibition of Abeta 42 by Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA) at different concentrations by Thioflavine T (ThT) method
A solution of Abeta 42 with a final concentration of 25 mu M is prepared, 0.25,0.50,1.00 and 2.00mg/mL of lpLTA are added, 25 mu M of ThT dye is added, the mixture is fully and uniformly mixed and placed in an enzyme-labeled instrument, the mixture is continuously cultured at 37 ℃ and fluorescence of a sample is detected every 1h, the detection condition is that the excitation light wavelength is 440nm, the emission light wavelength is 480nm, and the result of the ThT fluorescence is shown in figure 3.
Referring to FIG. 3, the fluorescence intensity of Abeta 42 itself gradually increased over time, reaching a plateau after 24h, and the fluorescence intensity of Abeta 42 solution also gradually increased over time after 0.25mg/mL of lpTLA was added, but reaching a plateau after 12h, with a maximum fluorescence intensity of about 60% of the maximum fluorescence value of the blank, indicating that Abeta 42 aggregation was inhibited by lpTLA. After addition of 0.50,1.00,2.00mg/mL of lpLTA, the fluorescence intensity of the Abeta 42 solution was hardly changed, indicating that the aggregation of Abeta 42 was completely inhibited by high concentration of lpLTA. In summary, lpTLA has a good inhibition effect on Abeta 42 aggregation, and Abeta 42 aggregation can be completely inhibited at a concentration of 0.50 mg/mL.
Example 4: the influence of Lactobacillus plantarum MA2 lipoteichoic acid (lpLTA) on Abeta 42 aggregation to form fibers is observed by using an atomic force microscope
The result of adding lpLTA at a final concentration of 0.50mg/mL to 25. Mu. M A. Beta.42 solution, culturing at 37℃for 48 hours, and then detecting the aggregation of Aβ42 in the presence or absence of lpLTA to form a fiber by atomic force microscopy is shown in FIG. 4,
Referring to FIG. 4, Aβ42 aggregates into distinct fiber morphology after 48h of culture, and is between about 200-1200nm in length. And after 0.50mg/mL lpLTA is added, the aggregation of Abeta 42 is inhibited, no obvious long fibers appear, and further the lpLTA can effectively inhibit the aggregation of Abeta 42, thus the inhibitor is a potential Abeta 42 aggregation inhibitor.
The application of the patent application CN 112386614A-lactobacillus plantarum MA2 in the aspect of preparing medicines or foods for preventing or improving AD is application of the lactobacillus plantarum MA2, and the invention further extracts and identifies lipoteichoic acid of the lactobacillus plantarum MA2 and explores the application of the lipoteichoic acid in the aspect of inhibiting the aggregation of AD pathogenic protein Abeta 42, and has the following advantages: (1) More deeply and specifically demonstrates the effect of the lactobacillus plantarum MA2 on relieving AD, and provides theoretical support for researching the action mechanism of the lactobacillus plantarum MA 2; (2) 0.5mg/mL lpLTA lipoteichoic acid can completely inhibit aggregation of Abeta 42, and the lactobacillus plantarum MA2 has no function; (3) The lpLTA lipid phosphorus wall has stable acidic property, easy storage and low energy consumption in the preparation process; (4) Can be accurately added into functional foods, beverages, health products and other products in various forms quantitatively, and is also helpful for developing AD-resistant medicaments.
A great deal of researches show that the aggregation of the Abeta 42 is a key factor for the occurrence and the development of the AD, the inhibition of the aggregation and the deposition of the Abeta 42, and the development of new anti-AD medicines based on the Abeta 42 are hot spots in the current medical field, and are one of effective ways for preventing and treating the AD. The lipoteichoic acid of the lactobacillus plantarum MA2 is obtained through ultrasonic crushing, hydrophobic gel filtration chromatography, ion exchange chromatography separation and extraction, the structure of the lipoteichoic acid is primarily analyzed through infrared spectrum and nuclear magnetic resonance, and the application of the lipoteichoic acid in inhibiting the aggregation of amyloid A beta 42 is provided and verified by using ThT fluorescent staining and atomic force microscope analysis. The present invention has been described by way of example of implementation, and it will be apparent to those skilled in the relevant art that modifications and variations can be made in the methods herein to practice the technology of the invention without departing from the spirit or scope of the invention. It should be understood that the above description is only illustrative of the preferred embodiments of the present invention and should not be taken as limiting the invention, but rather, all similar substitutes and modifications apparent to those skilled in the art are deemed to be included within the spirit, scope and content of the invention.
Claims (4)
1. Use of lactobacillus plantarum lipoteichoic acid for the preparation of a medicament for the prevention and/or amelioration of a disease characterized by the aggregate deposition of beta-amyloid 1-42 (aβ42), characterized in that: the disease is Alzheimer disease, the main chain of lipoteichoic acid of the lactobacillus plantarum contains glycerol, the side chain of the lipoteichoic acid contains N-acetylglucosamine and alanine modification, the lactobacillus plantarum is used for preparation, lactobacillus plantarum MA2 is separated and screened for the laboratory, the lactobacillus plantarum MA2 is derived from Tibetan farmhouse Kefir grains and is preserved in the China general microbiological culture Collection center with the preservation number of CGMCC3005; the preparation process comprises the steps of separation, extraction and purification, and comprises the following specific steps:
(1) Inoculating lactobacillus plantarum MA2 into MRS liquid culture medium, and culturing in a 37 ℃ incubator for 16-20h;
(2) Taking the bacterial liquid in the step (1), centrifuging the bacterial liquid in a centrifugal cup at 4 ℃ and 7000rpm for 20min, collecting bacterial cells, and weighing the wet weight of the bacterial cells;
(3) Re-suspending wet bacteria in 0.1M sodium citrate buffer solution with pH of 4.7 according to the ratio of 1:1 (w/v), repeatedly freezing and thawing for 3 times, and crushing the bacteria by using an ultrasonic crusher to obtain mixed bacterial suspension, wherein the amplitude is 30%, the opening is 1s, the closing is 1s, and the total working time is 30min;
(4) Adding equal volume of n-butanol into the mixed bacterial suspension obtained in the step (3), fully mixing, stirring for 30min on a magnetic stirrer, centrifuging at 7000rpm for 30min at 4 ℃, and gently collecting a lower water phase;
(5) Performing rotary evaporation and dialysis on the water phase, and intercepting lipoteichoic acid with the molecular weight of 2000Da by a dialysis bag to obtain a lipoteichoic acid crude extract;
(6) Preparing a2 x 20cm octyl-Sepharose gel column, equilibrated with 0.1M sodium acetate buffer at pH 4.7 containing 15% n-propanol;
(7) Mixing and diluting the lipoteichoic acid crude extract obtained in the step (5) with 0.1M sodium acetate buffer solution with the pH of 4.7 according to the volume ratio of 1:5, and passing through a column;
(8) Washing with 0.1M sodium acetate buffer of pH 4.7 of 15% n-propanol to remove unbound impurities;
(9) The column was eluted with a gradient of 0.1M sodium acetate buffer pH 4.7 containing 20%, 35%, 45% n-propanol, and the eluate was collected in a 10mL centrifuge tube;
(10) Detecting inorganic phosphorus in the eluent, and collecting the eluent with higher phosphorus content for rotary evaporation and dialysis;
(11) Preparation of DEAE-FastFlow 1.5 x 10cm anion chromatography column secondary purification of lipoteichoic acid, equilibrated column with 0.1M sodium acetate buffer at pH 4.7 containing 30% n-propanol;
(12) Pretreating the eluent after dialysis in (10) and loading the eluent on a column, performing gradient elution by using 0-1M sodium chloride solution, and collecting the eluent by using a 10 mL/tube; the sodium chloride solution is prepared by 0.1M sodium acetate buffer solution;
(13) Detecting inorganic phosphorus in the eluent collected in the step (12), and collecting the eluent with higher phosphorus content for rotary evaporation and dialysis;
(14) Freezing the dialysate obtained in the step (13) for 4 hours at the temperature of minus 80 ℃ in advance, then placing the dialysate into a freeze dryer, and obtaining lactobacillus plantarum MA2 lipoteichoic acid solid after sublimation and drying, and freezing and preserving the lactobacillus plantarum MA2 lipoteichoic acid solid.
2. The use according to claim 1, characterized in that: the lactobacillus plantarum MA2 lipoteichoic acid exists in an aqueous dispersion system.
3. The use according to claim 1, characterized in that: the lactobacillus plantarum MA2 lipoteichoic acid is present in an aqueous dispersion having a concentration of 0.25,0.50,1.00,2.00 mg/mL.
4. The use according to claim 3, wherein said lactic acid producing agent in the form of an aqueous dispersion is formulated as an injection, injectable solution, soft capsule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111332410.2A CN114099555B (en) | 2021-11-11 | 2021-11-11 | Lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111332410.2A CN114099555B (en) | 2021-11-11 | 2021-11-11 | Lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114099555A CN114099555A (en) | 2022-03-01 |
| CN114099555B true CN114099555B (en) | 2024-01-09 |
Family
ID=80378421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111332410.2A Active CN114099555B (en) | 2021-11-11 | 2021-11-11 | Lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114099555B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068510A (en) * | 2022-05-24 | 2022-09-20 | 宁波大学 | Extraction method of lactobacillus lipoteichoic acid and anti-inflammatory activity application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10273496A (en) * | 1997-03-31 | 1998-10-13 | Chugai Pharmaceut Co Ltd | Lipoteichoic acid |
| CN103355620A (en) * | 2012-03-28 | 2013-10-23 | 天津科技大学 | Prepared method of pickled celery through lactobacillus fementation |
| KR20190017168A (en) * | 2017-08-10 | 2019-02-20 | 서울대학교산학협력단 | A Pharmaceutical composition for Regenerating skin and Treating wounds Containing Lipoteichoic acid |
| KR20210080182A (en) * | 2019-12-20 | 2021-06-30 | 경희대학교 산학협력단 | Composition for preventing and treating of obesity comprising powder of lactic acid cell lysate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3406731A1 (en) * | 2017-05-22 | 2018-11-28 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Metabolic labeling of bacterial teichoic acids cell wall |
-
2021
- 2021-11-11 CN CN202111332410.2A patent/CN114099555B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10273496A (en) * | 1997-03-31 | 1998-10-13 | Chugai Pharmaceut Co Ltd | Lipoteichoic acid |
| CN103355620A (en) * | 2012-03-28 | 2013-10-23 | 天津科技大学 | Prepared method of pickled celery through lactobacillus fementation |
| KR20190017168A (en) * | 2017-08-10 | 2019-02-20 | 서울대학교산학협력단 | A Pharmaceutical composition for Regenerating skin and Treating wounds Containing Lipoteichoic acid |
| KR20210080182A (en) * | 2019-12-20 | 2021-06-30 | 경희대학교 산학협력단 | Composition for preventing and treating of obesity comprising powder of lactic acid cell lysate |
Non-Patent Citations (1)
| Title |
|---|
| The Effect of Lipoteichoic Acid from Lactobacillus plantarum on Dental Pulp Inflammation;Nirawati Pribadi等;《Eur J Dent .》;第15卷(第4期);第682-686页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114099555A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adebayo-Tayo et al. | Characterization, antioxidant and immunomodulatory potential on exopolysaccharide produced by wild type and mutant Weissella confusa strains | |
| KR101494279B1 (en) | Lactobacillus plantarum KY1032 having inhibitory activity against adipocyte-specific gene expression and adipocyte differentiation, and product containing thereof as an effective factor | |
| CN110157647B (en) | Lactobacillus brevis capable of relieving anxiety and improving sleep and application thereof | |
| CN103655637B (en) | Pharmaceutical application of Lactobacillus plantarum CMU995 strain | |
| KR102033031B1 (en) | Lactobacillus plantarum tci378 and its uses in losing fat and improving gastrointestinal functions | |
| CN110522035B (en) | Human-derived probiotic and application thereof in assisting blood sugar reduction | |
| CN103619343A (en) | Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies | |
| EP1794283A1 (en) | Metabolically active micro organisms and methods for their production | |
| CN109182162B (en) | Lactobacillus plantarum with antioxidant capacity and application thereof | |
| JP2020524999A (en) | Nanovesicle derived from Proteus bacterium and its use | |
| JP7264531B2 (en) | Morganella-derived nanovesicles and uses thereof | |
| CN114099555B (en) | Lactobacillus plantarum lipoteichoic acid and application thereof in inhibiting amyloid aggregation | |
| KR20230154400A (en) | Lactobacillus plantarum hom3201 strain and its live bacterial preparation, preparation method and application | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN115927045B (en) | Lactobacillus salivarius 069 with cholesterol reducing and liver injury relieving functions caused by hyperlipidemia and application thereof | |
| CN115369050B (en) | SJ-2 strain of Teng Senshi microcins and application thereof | |
| KR101266328B1 (en) | Lactobacillus gasseri HY7021 having inhibitory activity against adipocyte-specific gene expression and adipocyte differentiation, and product containing thereof as an effective factor | |
| AU2014378873A1 (en) | Extracellular polysaccharide with immunomodulatory effect and preparation method and use thereof | |
| KR102499838B1 (en) | Lactobacillus paracasei strain or Lactobacillus plantarum strain derived from human having body fat reducing activity and mixture composition comprising the same | |
| CN116178509B (en) | Preparation method and application of bifidobacterium surface protein | |
| CN113604391B (en) | Application of litchi pulp flavonoid extract in preparation of lactobacillus proliferation promoting and pathogenic bacteria adhesion resisting preparation | |
| CN114921383A (en) | Probiotic preparation with cholesterol removing function and preparation method thereof | |
| CN115838661A (en) | Lactobacillus plantarum magpie gentlemen 18, lactobacillus plantarum preparation and application thereof | |
| CN114085791A (en) | Pediococcus pentosaceus He10-a-1 and application thereof | |
| CN103224895B (en) | Novel lactobacillus lodelbrueckii strain and application thereof in improving autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |